163 related articles for article (PubMed ID: 12593470)
1. Apolipoprotein CIII and highly active antiretroviral therapy (HAART)-induced hypertriglyceridemia.
Badiou S; Dupuy AM; Baillat V; Fabre J; Tur MD; Cristol JP; Reynes J
Clin Lab; 2003; 49(1-2):11-3. PubMed ID: 12593470
[No Abstract] [Full Text] [Related]
2. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
[TBL] [Abstract][Full Text] [Related]
3. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy.
Baril L; Beucler I; Valantin MA; Bruckert E; Bonnefont-Rousselot D; Coutellier A; Caumes E; Katlama C; Bricaire F
AIDS; 2001 Feb; 15(3):415-7. PubMed ID: 11273223
[No Abstract] [Full Text] [Related]
4. [HAART influences the lipids].
Behrens G
MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
[No Abstract] [Full Text] [Related]
5. Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
Ware LJ; Jackson AG; Wootton SA; Burdge GC; Morlese JF; Moyle GJ; Jackson AA; Gazzard BG
Br J Nutr; 2009 Oct; 102(7):1038-46. PubMed ID: 19480729
[TBL] [Abstract][Full Text] [Related]
6. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
[TBL] [Abstract][Full Text] [Related]
7. Management of hypertriglyceridaemia caused by combination antiretroviral therapy in HIV-infected patients: role of omega-3 polyunsaturated fatty acids at different dosages, compared with fibrates.
Manfredi R
Int J STD AIDS; 2010 Jan; 21(1):73-4. PubMed ID: 19843616
[No Abstract] [Full Text] [Related]
8. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
Tarr PE; Taffé P; Bleiber G; Furrer H; Rotger M; Martinez R; Hirschel B; Battegay M; Weber R; Vernazza P; Bernasconi E; Darioli R; Rickenbach M; Ledergerber B; Telenti A;
J Infect Dis; 2005 May; 191(9):1419-26. PubMed ID: 15809899
[TBL] [Abstract][Full Text] [Related]
9. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
[TBL] [Abstract][Full Text] [Related]
10. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients.
Fernández Cotarelo MJ; Abellán Martínez J; Guerra Vales JM; Martínez Sánchez P; Rodrigo Gómez De La Bárcena M; Salto Fernández E
Clin Infect Dis; 2003 Oct; 37(7):973-7. PubMed ID: 13130410
[TBL] [Abstract][Full Text] [Related]
11. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
[TBL] [Abstract][Full Text] [Related]
12. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
13. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A
J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202
[No Abstract] [Full Text] [Related]
14. Considerations on the increase in blood pressure among antiretroviral-naive patients starting HAART.
Martínez E; López Bernaldo de Quirós JC; Miralles C; Podzamczer D
AIDS; 2007 Jan; 21(3):384-6. PubMed ID: 17255753
[No Abstract] [Full Text] [Related]
15. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.
Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Solinas P; Mannazzu M; Falchi A; Mura MS; Madeddu G
Clin Endocrinol (Oxf); 2006 Apr; 64(4):375-83. PubMed ID: 16584508
[TBL] [Abstract][Full Text] [Related]
16. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
[TBL] [Abstract][Full Text] [Related]
18. HIV viremia and the development of AIDS-related lymphoma in patients treated with highly active antiretroviral therapy.
Sabin CA
J Infect Dis; 2009 Jul; 200(1):8-10. PubMed ID: 19476436
[No Abstract] [Full Text] [Related]
19. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
20. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
Sabundayo BP; McArthur JH; Langan SJ; Gallant JE; Margolick JB
Pharmacotherapy; 2006 May; 26(5):674-81. PubMed ID: 16637796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
